Firm halting sales of dietary supplement Anatabloc

by Michael Felberbaum

The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife says it's halting sales of its product called Anatabloc.

Rock Creek Pharmaceuticals Inc. said Monday it is voluntarily stopping sales while it sorts out issues with the Food and Drug Administration.

Last year, the federal agency sent a warning letter to the company known as Star Scientific saying that its products contain a new dietary ingredient that requires approval before it can be marketed.

The agency also said the company's website had improperly promoted Anatabloc as a drug by suggesting it can be used to treat various diseases.

The McDonnells are charged with accepting gifts and loans from Star Scientific's former CEO in exchange for promoting his products.

4 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA warns of steroids in vitamin B supplement

Jul 27, 2013

(AP)—The Food and Drug Administration is warning consumers to avoid a vitamin B dietary supplement from Healthy Life Chemistry by Purity First because it contains two potentially dangerous anabolic steroids.

Orbactiv approved for drug-resistant skin infections

Aug 07, 2014

(HealthDay)—The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.

Virginia tobacco maker seeks new FDA designation

Jan 04, 2011

(AP) -- Tobacco maker Star Scientific Inc. says it has developed a moist smokeless tobacco with lower levels of cancer-causing chemicals than any other tobacco product now on the market.

US watchdog warns on fitness stimulant

Apr 27, 2012

The US Food and Drug Administration on Friday questioned the safety of DMAA, a stimulant used in dietary supplements, alleging that marketers were illegally selling the chemical.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments